Who is sponsoring NCT04462653?

NCT04462653 is sponsored by Huami Corporation.

What drugs are being tested in NCT04462653?

Interventions in NCT04462653: Wearable Dynamic ECG Recorder, 12-lead ECG recordings.

What condition does NCT04462653 study?

NCT04462653 studies Atrial Fibrillation.

Is NCT04462653 still recruiting?

NCT04462653 is currently status unknown. Last updated 8 July 2020.

Last reviewed 2020-07-08 · How we verify

NCT04462653

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Detection of Atrial Fibrillation by a Wearable Dynamic ECG Recorder

Status unknown NA Last updated 8 July 2020

What this trial tests

NA trial testing Wearable Dynamic ECG Recorder in Atrial Fibrillation in 114 participants. Status unknown.

Timeline

24 April 2020

Primary endpoint
1 August 2020

1 September 2020

Quick facts

Lead sponsor	Huami Corporation
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	114
Start date	24 April 2020
Primary completion	1 August 2020
Estimated completion	1 September 2020
Sites	1 location across China

Drugs / interventions tested

Wearable Dynamic ECG Recorder
12-lead ECG recordings

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

Huami Corporation

Who can join

Adults 18 to 80, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Randomized, Crossover Trial is conducted to Evaluate Consistency Atrial fibrillation diagnosis between the Wearable Dynamic ECG Recorder and the Control device. In this investigation, the following indicators is also evaluated: 1. Sensitivity and specificity of the ECG App algorithm in detecting atrial fibrillation compared with physician-adjudicated Gold Standard ECG recorder. 2. Waveform qualitative assessment 3. Safety incident assessments. 114 subjects (60 healthy subjects in phase I and 54 subjects with atrial fibrillation diagnosis in phase II) are enrolled in the investigation according to the criteria.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04462653 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huami Corporation
Last refreshed: 8 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04462653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing